PS
LXRX icon

Pinney & Scofield’s Lexicon Pharmaceuticals LXRX Stock Holding History

Pinney & Scofield’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,000
Closed -$461 – 221
2025
Q1 		$461 Hold
1,000
– – ﹤0.01% 212
2024
Q4 		$739 Buy
+1,000
New +$1.21K ﹤0.01% 219

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pinney & Scofield's LXRX Position: Q2 2025 in Review

Pinney & Scofield sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2025, closing a stake of 1,000 shares — an estimated $461 sold.

Pinney & Scofield first reported a position in LXRX in Q4 2024 and held it in 2 quarters. The position peaked at $739 in Q4 2024. 123 funds tracked by Wall St. Rank hold LXRX as of Q2 2025.

  • Pinney & Scofield reported no remaining Lexicon Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Pinney & Scofield sold 1,000 Lexicon Pharmaceuticals shares in Q2 2025, an estimated $461.
  • Pinney & Scofield first reported a position in Lexicon Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Pinney & Scofield's Lexicon Pharmaceuticals position peaked at $739 in Q4 2024.
  • 123 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2025.

Based on Pinney & Scofield's 13F filing for Q2 2025, filed 8 Aug 2025.